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(e most recent British(oracic Society/Intensive Care Society (BTS/ICS) guidelines on the use of noninvasive ventilation (NIV)
in acute hypercapnic respiratory failure (AHRF) suggest to maximize NIV use in the first 24 hours and to perform a slow tapering.
However, a limited number of studies evaluated the phase of NIV weaning. (e aim of this study is to describe the NIV weaning
protocol used in AHRF due to acute exacerbation of chronic obstructive pulmonary disease (AE-COPD), patients’ characteristics,
clinical course, and outcomes in a real-life intermediate respiratory care unit (IRCU) setting. We performed a retrospective study
on adult patients hospitalized at the IRCU of San GerardoHospital, Monza, Italy, from January 2015 to April 2017 with a diagnosis
of AHRF due to COPD exacerbation. (e NIV weaning protocol used in our institution consists of the interruption of one of the
three daily NIV sessions at the time, starting from the morning session and finishing with the night session. (e 51 patients who
started weaning were divided into three groups: 20 (39%) patients (median age 80 yrs, 65%males) who completed the protocol and
were discharged home without NIV (Completed Group), 20 (39%) did not complete it because they were adapted to domiciliary
ventilation (Chronic NIV Group), and 11 (22%) interrupted weaning ex abrupto mainly due to NIV intolerance (Failed Group).
Completed Group patients were older, had a higher burden of comorbidities, but a lower severity of COPD compared to Chronic
NIV Group. Failed Group patients experienced higher frequency of delirium after NIV discontinuation. None of the patients who
completed weaning had AHRF relapse during hospitalization.While other NIV weaning methods have been previously described,
our study is the first to describe a protocol that implies the interruption of a ventilation session at the time. (e application of a
weaning protocol may prevent AHRF relapse in the early stages of NIV interruption and in elderly frail patients.
1. Introduction
Bilevel noninvasive ventilation (NIV) is a milestone in the
treatment of acute hypercapnic respiratory failure (AHRF)
in patients with acute exacerbation of chronic obstructive
pulmonary disease (AE-COPD) [1, 2]. Unfortunately, only a
limited number of studies evaluated the weaning from NIV
once acidosis and respiratory distress are solved, proposing
different weaning methods but not clearly establishing the
superiority of one over the others [3–6]. A recently pub-
lished randomized controlled trial (RCT) questioned the
utility of the weaning phase [5]. In this RCT, Sellares et al.
compared the prolongation of NIV for three nights after
recovery from an AHRF episode to direct NIV
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discontinuation in COPD patients without previous do-
miciliary ventilation [5]. No differences were observed in
regard to prevention of AHRF relapse, hospital readmission,
or mortality [5]. Furthermore, the application of a weaning
phase resulted in a prolonged intermediate respiratory care
unit (IRCU) stay. (ese results seem to suggest that NIV can
be directly discontinued once the acute episode is solved.
However, as in all RCTs, very elderly patients, not fully
cooperative and with several comorbidities, have rarely been
included, although they often represent a consistent part of
the COPD population with AHRF admitted to IRCUs [5]. In
such a frail group, many factors may play a role in AHRF
relapse after NIV discontinuation, including other re-
spiratory comorbidities, delirium, and sarcopenia [7].
(erefore, the actual need of weaning from NIV in a real-life
cohort of patients with AHRF and AE-COPD and the best
way to perform it still need to be determined.
Our aim is to present and test the feasibility of the NIV
weaning strategy used in patients with AHRF due to AE-
COPD admitted in our IRCU. Furthermore, we describe the
characteristics, clinical course, and outcomes of the cohort of
patients who underwent the NIV weaning protocol.
2. Materials and Methods
2.1. Study Design. (is was a retrospective cohort study on
adult patients hospitalized in the IRCU of San Gerardo
Hospital, Monza, Italy, from January 2015 to April 2017 with
a diagnosis of AE-COPD. (e study was approved by the
local Institutional Review Board (#684-May 2017) and did
not require patients’ informed consent due to the retro-
spective design.
(e following data were retrospectively collected from
patients’ charts: demographics, comorbidities and Charlson
comorbidity index [8], COPD characteristics (including
pulmonary function tests performed at the previous avail-
able outpatient visit during clinical stability, number of
exacerbations and hospitalizations during the prior year, and
COPD phenotype—emphysema, chronic bronchitis,
asthma-COPD overlap, and bronchiectasis-COPD overlap
[9, 10]), severity scores at admission (acute physiology and
chronic health disease classification system II (APACHE II)
[11] and sequential organ failure assessment (SOFA) [12]),
radiological imaging during hospitalization (either chest
X-ray, computerized tomography scan, or both), arterial
blood gases (ABG), days of NIV application and hospital
length of stay, presence of delirium during hospitalization,
and NIV parameters. Follow-up data, including three-
month mortality and hospitalization rate, were also retro-
spectively collected from outpatient clinic charts. All pa-
tients discharged from our IRCU with a diagnosis of AE-
COPD were followed-up after 3months from discharge at
our COPD outpatient clinic; those who did not present at the
visit received a phone call to reprogram it.
2.2. AE-COPD Definition. AE-COPD was defined as acute
worsening of respiratory symptoms that resulted in addi-
tional therapy, including antibiotics, systemic
corticosteroids, and increased bronchodilator therapy [13].
In our study population, AE-COPD was the primary ad-
mission diagnosis according to the physician in charge.
Patients who also had pneumonia or congestive heart failure
as secondary diagnoses were not excluded from the study,
and these variables were reported in the Results section.
2.3. NIV Initiation Criteria and Indication to Chronic Do-
miciliary NIV. In accordance with the protocol adopted by
our institution, bilevel NIV was initiated in patients with
AHRF (arterial carbon dioxide partial pressure (PaCO2)
> 45mmHg) due to AE-COPD in case of respiratory acidosis
(pH≤ 7.35) and/or respiratory distress. Respiratory distress
was defined as the respiratory rate (RR)> 25 associated with
use of respiratory accessory muscles. In case of pH< 7.25,
decision regarding NIV initiation was shared with the in-
tensive care unit (ICU) team.
All patients were ventilated with pressure support
ventilation modality. (e ventilators available in our IRCU
were Respironics Esprit and Resmed Elisée 150. Full face and
oronasal interfaces were used.
In our institution, indications for domiciliary NIV in
COPD patients were persistent daytime hypercapnia after at
least two episodes of AHRF requiring NIV in the prior year;
and comorbidities such as obstructive sleep apnea or
obesity-hypoventilation syndrome, in accordance with
guidelines for each disease [1, 14, 15].
2.4. NIV Disconnection and NIVWeaning Initiation Criteria.
NIV disconnection was attempted when all the following
were concurrently met:
(a) Adequate oxygenation defined as arterial oxygen
partial pressure to fraction of inspired oxygen ratio
(PaO2/FiO2)> 200mmHg during NIV with fraction
of inspired oxygen (FiO2)< 0.5
(b) pH> 7.35, RR< 25 without use of respiratory ac-
cessory muscles
(c) Hemodynamic stability (assessed through heart rate
and blood pressure)
(d) Kelly score [16]≤ 2
(e weaning phase began when all the following criteria
were reached after at least 1 hour of disconnection fromNIV
and by administering oxygen through a venturi mask with a
FiO2 titrated in order to maintain peripheral oxygen satu-
ration (SpO2) 88–92%:
(a) pH> 7.35, RR< 25 without use of respiratory ac-
cessory muscles
(b) Hemodynamic stability
(c) Kelly score [16]≤ 2
2.5. NIV Weaning Protocol. (e weaning protocol used in
our institution is summarized in Figure 1. (e term “NIV
session” was used to indicate the continuous application of
NIV for at least 3 hours to the maximum duration tolerated
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by the patient, with interruption only for oral therapy ad-
ministration and/or feeding. During the acute initial phase,
the treatment is maximized with 3 NIV sessions per day
(morning, afternoon, and night) (Figure 1). In our NIV
weaning protocol, the patient starts NIV weaning with in-
terruption of the morning session. If there is no recurrence
of respiratory distress or AHRF, the patient continues
weaning with interruption of the afternoon session and, for
last, of the nocturnal session. (e NIV sessions were
interrupted one per day (e.g., day 1: interruption of the
morning session; day 2: interruption of the morning and
afternoon session; day 3: interruption of all ses-
sions—morning, afternoon, and night). (e number of days
at each stage of weaning (NIV during afternoon and night or
nocturnal NIV only) was at physician discretion. During
weaning, NIV pressures, both inspiratory positive airway
pressure (IPAP) and expiratory positive airway pressure
(EPAP), were maintained on the same personalized settings
used to reverse AHRF.
During NIV weaning, every patient underwent pul-
monary rehabilitation between NIV sessions with positive
expiratory pressure (PEP) and incentive spirometry (IS)
devices. In patients with residual mucus encumbrance, we
used PEP devices (i.e., PEP bottle or (eraPEP, Smiths
Medical) set at low pressure (8 cmH2O) asking the patient to
blow as long as possible repeatedly without achieving fa-
tigue, in order to improve airway clearance. In patients with
poor thoracoabdominal movements, we used IS devices in
association with stretching exercises aimed at preventing
atelectasis or local hypoventilation. (e patient was invited
to repeatedly inspire slowly through the device (Coach II,
Smiths Medical) lifting a piston up to the limit set at 70–80%
of inspiratory capacity and then hold breath for five seconds.
Pulmonary rehabilitation was set and carried out by a re-
spiratory therapist up to two times per day; additional
sessions were kept by nurses.
NIV weaning failure occurred if any of the following
appeared during the execution of the NIV weaning protocol:
(a) pH≤ 7.35 and/or respiratory distress
(b) Hemodynamic instability
(c) Kelly score [16]> 2
2.6. Delirium Definition and Criteria for Identification.
(e chart-based method (CBM) was used to retrospectively
identify delirium on patients’ charts [17, 18], searching for
key terms for identification of delirium (inattention, dis-
orientation, hallucinations, agitation, and inappropriate
behavior) and for any evidence of acute mental status
change.
We temporally divided the presence of delirium into two
subgroups: delirium during NIV and delirium after NIV
discontinuation, in order to evaluate the possible role of this
complication in association with NIV weaning and clinical
outcomes.
2.7. Outcomes. (e following outcomes were considered for
all patients who initiated the weaning phase:
(i) Primary outcomes: new worsening of gas exchange
(pH≤ 7.35, RR> 25, and/or respiratory distress)
after completion of weaning protocol and in-hospital
mortality
(ii) Secondary outcomes: three-month mortality and
three-month hospitalization rate
2.8. Statistical Analysis. Data were analyzed using SPSS 21.0
for MAC OS (SPSS Inc., Chicago, IL, USA). Baseline
characteristics of the study population, ABGs, ventilation
parameters, and outcomes, were considered for statistical
analysis. We assessed normality distribution for continuous
variables with the Kolmogorov–Smirnov test. Continuous
variables were expressed as median (interquartile range
(IQR): 25th–75th percentile) and compared using the
Kruskal–Wallis nonparametric ANOVA test. Categorical
data were expressed as frequencies and percentages and
compared using the chi-square test. All tests were 2-tailed,
and a P value< 0.05 was considered statistically significant.
3. Results
3.1. Characteristics of Study Population. Among the 94 pa-
tients hospitalized in the IRCU with a diagnosis of COPD
exacerbation during the study period, we focused on 51
patients (median age 79 yrs, 53%males) who were started on
NIV weaning after an episode of AHRF (Figure 2).
Of these 51 patients, 20 (median age 80 yrs, 65% males)
completed the protocol (Completed Group), 20 (median age
65 yrs, 35% males) did not complete the weaning because
they were adapted to chronic domiciliary ventilation
(Chronic NIV Group), and 11 (median age 82 yrs, 65%
males) did not complete the protocol for other clinical
conditions (Failed Group) (Figure 2).
Clinical conditions for which Failed Group did not
complete weaning included NIV intolerance, high risk of
pneumothorax due to severe bullous emphysema, and NIV
weaning failure, as defined in Section 2, which required an
Acute phase: respiratory distress and/or AHRF 
Maximize NIV use with 3 sessions/day (morning, afternoon, and night) 
for at least 3 hours per session
Resolution of respiratory distress and/or AHRF
Start NIV weaning with interruption of morning session
Recurrence of respiratory distress and/or AHRF?
No Yes
Continue weaning with 
interruption of afternoon session 
and, for last, night session 
Consider to reincrease NIV 
sessions
Figure 1: NIV weaning protocol. AHRF, acute hypercapnic re-
spiratory failure; NIV, noninvasive ventilation.
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increase in NIV sessions (Figure 2). None of the 51 patients
developed facial skin lesion; however, three patients de-
veloped gastric distension associated with nausea in one case.
Demographics, comorbidities, and COPD characteristics
of the three study groups are summarized in Table 1.
Completed Group patients were older and had a higher
burden of comorbidities, evaluated through the Charlson
index. In regard to specific comorbidities, Completed Group
presented the highest frequency of cardiovascular diseases,
while Chronic NIV Group showed more frequently obesity-
hypoventilation syndrome and mood disorders. Patients in
Completed Group presented more frequently a chronic
bronchitis phenotype and had a lower number of COPD
exacerbations and hospitalizations in the prior year. How-
ever, this finding is related to the definition itself of patients
in “Chronic NIV Group” that had to present at least two
episodes of AHRF, requiring NIV in the prior year to receive
chronic nocturnal domiciliary NIV. Only two patients in
Completed Group received a do-not-resuscitate/do-not-
intubate (DNR/DNI) order, which was significantly less
frequent than in Failed Group.
(ere was no between-group difference in the prevalence
of delirium during NIV and during hospitalization as a
whole (Table 1). (e prevalence of delirium after NIV
discontinuation, however, was greater in the Failed Group
than in the Completed Group.
3.2. Severity on Admission and Arterial Blood Gases
Evaluation. APACHE II score was greater in the Failed
Group compared to the other two study groups. In contrast,
there was no between-group difference in the SOFA score
(Table 2). Also, pH values of the ABG performed at ad-
mission were lower in Completed Group and Failed Group
in comparison with Chronic NIV Group (7.30, 7.29, and
7.35, respectively; P value<0.01) (Figure 3). (ere were no
between-group differences in concomitant causes of AHRF
(Table 2).
Furthermore, we analyzed the ABGs performed at dif-
ferent stages both during and after NIV discontinuation
(Figure 3). No difference was observed between groups with
the exception of lower PaCO2 values in Completed Group
and Failed Group compared to Chronic NIVGroup at ABGs
performed at 24 and 48 h after NIV discontinuation, but not
at the ABG performed at discharge.
3.3. NIV Duration and Parameters. Compared to the
Completed Group, the duration of NIV was shorter in the
Failed Group and longer in the Chronic NIV Group (for the
latter group, days on nocturnal domiciliary NIV were in-
cluded in the computation of total NIV duration, because it
was artificial to exactly locate the moment when weaning
was finished) (Table 3). However, no differences were found
94 patients admitted to the IRCU with a diagnosis of AE-COPD
65 patients with respiratory distress and/or AHRF treated with NIV
51 patients with resolution of respiratory distress and/or 
AHRF who started NIV weaning
«Failed Group»
20 patients completed NIV 
weaning as per protocol 
«Completed Group» 
«Chronic NIV Group»
29 excluded due to absence of respiratory
distress and/or AHRF: 
13 not treated with NIV
12 continued usual domiciliary NIV
2 patients with tracheostomy in usual
domiciliary invasive mechanical ventilation




14 cases of NIV failure: 
11 patients with worsening of underlying 
disease
3 patients due to NIV intolerance
(i)
11 patients did not complete NIV weaning
protocol: 
9 early discontinuation due to NIV 
intollerance
1 early discontinuation due to high risk of
pneumothorax
1 due to worsening of respiratory failure




20 patients in domiciliary NIV: 
13 patients readapted to 
usual domiciliary NIV






Figure 2: Flow chart of study population. IRCU, intermediate respiratory care unit; COPD, chronic obstructive pulmonary disease; AHRF,
acute hypercapnic respiratory failure; NIV, noninvasive ventilation.
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Age (yrs), median (IQR) 79 (74–85) 65 (55–75) 82 (77–84) <0.01
Males 13 (65) 7 (35) 7 (64) 0.65
BMI (kg/m2), median (IQR) 24.9 (21.1–27.1) 26.2 (24.6–29.1) 23.9 (21–23.4) 0.12
Current or prior smokers 20 (100) 20 (100) 11 (100) —
Do-not-resuscitate order 2 (10) 1 (5) 5 (45) 0.02
Comorbidities, n (%)
Charlson comorbidity index, median (IQR) 6.75 (6-7) 4 (3–5) 7 (6–8) <0.01
Diabetes mellitus 4 (20) 2 (10) 2 (18) 0.09
Chronic heart diseases 12 (60) 4 (20) 4 (36) 0.09
Prior myocardial infarction 9 (45) 0 4 (36) 0.26
Cerebrovascular diseases 2 (10) 3 (15) 2 (18) 0.51
Chronic liver disease 2 (10) 1 (5) 0 0.25
Solid tumor 2 (10) 1 (5) 2 (18) 0.59
Hematologic malignancy 1 (5) 0 0 0.28
Obstructive sleep apnea syndrome 1 (5) 4 (20) 1 (9) 0.055
Kyphoscoliosis 0 0 2 (18) 0.03
Obesity-hypoventilation syndrome 0 4 (20) 0 0.63
Dementia 0 0 0 —
Psychiatric disorders 2 (10) 9 (45) 3 (27) 0.16
Chronic renal failure 2 (10) 0 2 (18) 0.63
COPD characteristics, n (%)
FEV1 (L), median (IQR) 0.79 (0.62–0.99) 0.49 (0.36–0.82) 0.89 (0.69–1) 0.03
FEV1 (%), median (IQR) 42 (35–50) 33 (17–45) 40 (32–49) 0.21
GOLD 4∗ 16 (80) 15 (75) 7 (64) 0.60
Emphysema phenotype 3 (15) 0 5 (45) 0.87
Chronic bronchitis phenotype 15 (75) 9 (45) 4 (36) 0.03
Asthma-COPD overlap phenotype 2 (10) 7 (35) 2 (18) 0.39
Bronchiectasis-COPD overlap phenotype 0 3 (15) 0 0.68
No. of exacerbations in the previous year,
median (IQR) 1 (0-1) 3 (2–5) 1 (0–2) 0.07
No. of hospitalizations in the previous year,
median (IQR) 1 (0-1) 2 (0–5) 1 (0–2) 0.01
Long-term oxygen therapy 10 (50) 17 (85) 5 (45) 0.81
Prior domiciliary NIV 0 17 (85) 0 0.27
Delirium, n (%)
Delirium according to CBM 4 (20) 4 (20) 4 (36) 0.36
Delirium during NIV 4 (20) 4 (20) 3 (27) 0.68
Delirium after NIV discontinuation 0 — 3 (27) —
BMI, body mass index; CBM, chart-based method; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in the 1st second; GOLD,
global initiative for chronic obstructive lung disease; IQR, interquartile range 25th–75th percentile; NIV, noninvasive ventilation. ∗Classification of airflow
limitation severity based on postbronchodilator FEV1 [13].






(N � 11) P value
Severity scores, median (IQR)
Apache II 19 (17–21) 16 (15–19) 20 (14–21) 0.02
SOFA score 3 (2–4) 3 (2-3) 3 (2-3) 0.80
Concomitant causes of AHRF, n (%)
Pneumonia 5 (25) 5 (25) 4 (36) 0.55
Congestive heart failure 14 (70) 8 (40) 7 (64) 0.48
Vital parameters on admission, median
(IQR)
Respiratory rate 23 (20–30) 22 (20–34) 26 (24–32) 0.46
Heart rate 99 (90–117) 97 (81–109) 95 (87–114) 0.78
Mean arterial pressure 95 (86–123) 97 (91–106) 101 (90–130) 0.55
AHRF, acute hypercapnic respiratory failure; APACHE II, acute physiology and chronic health evaluation II; IQR, interquartile range 25th–75th percentile;
NIV, noninvasive ventilation; SOFA, sequential organ failure assessment.

















52 (43–66) 66 (62–72) 65 (57–72) 64 (56–69) 61 (55–66) 63 (60–65)
51 (46–60) 67 (61–70) 59 (52–73) 61 (56–63) 63 (55–68) 62 (59–67)
53 (41–61) 65 (61–69) 63 (61–78) 62 (55–66) 67 (60–75) 60 (58–61)
Completed Group (N = 20)
Chronic NIV Group (N = 20)
Failed Group (N = 11)
(a)
Median (IQR)








65 (58–73) 60 (51–69) 56 (47–66) 50 (48–53) 51 (47–54) 50 (45–54)
63 (57–73) 62 (51–70) 63 (56–68) 62 (49–66) 57 (51–63) 53 (49–61)
65 (54–78) 56 (46–68) 59 (43–65) 47 (43–51) 45 (44–56) 52 (48–55)
Completed Group (N = 20)
Chronic NIV Group (N = 20)
Failed Group (N = 11)
P value = 0.01
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between groups in regard to number of days with maximized
NIV before weaning (3 sessions per day) with a median of
one day for each group and length of hospital stay.
For patients in Completed Group and Failed Group,
lower NIV pressures (both IPAP and EPAP) were used in
comparison with Chronic NIV Group. In this latter group,
Median (IQR)








7.30 (7.26–7.34) 7.32 (7.29–7.36) 7.34 (7.32–7.38) 7.42 (7.39–7.46) 7.42 (7.40–7.44) 7.41 (7.39–7.43)
7.35 (7.30–7.38) 7.35 (7.31–7.37) 7.34 (7.32–7.37) 7.38 (7.36–7.41) 7.39 (7.37–7.41) 7.41 (7.38–7.42)
7.29 (7.27–7.35) 7.34 (7.31–7.38) 7.36 (7.31–7.42) 7.40 (7.36–7.42) 7.38 (7.33–7.40) 7.40 (7.36–7.44)
Completed Group (N = 20)
Chronic NIV Group (N = 20)







P value < 0.01
P value < 0.01
P value = 0.02
(c)
Median (IQR)








225 (185–287) 244 (214–269) 240 (208–282) 250 (227–292) 236 (230–270) 273 (228–296)
217 (184–247) 255 (214–278) 233 (216–271) 250 (238–266) 252 (231–266) 263 (243–293)
189 (132–223) 248 (224–290) 241 (225–339) 263 (214–280) 285 (200–226) 271 (218–321)
Completed Group (N = 20)
Chronic NIV Group (N = 20)









Figure 3: Arterial blood gases at different stages both during NIV and after NIV discontinuation. ABG, arterial blood gas; IQR, interquartile
range 25th–75th percentile; PaO2, arterial oxygen partial pressure (mmHg); PaCO2, arterial carbon dioxide partial pressure (mmHg); P/
F�PaO2/FiO2, arterial oxygen partial pressure to fraction of inspired oxygen ratio; NIV, noninvasive ventilation. (a) ABG: pO2, (b) ABG:
pH, (c) ABG: pCO2, and (d) ABG: P/F.
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NIV pressures used during the acute phase were similar to
those titrated for the chronic domiciliary NIV use, as shown
in Table 3.
3.4. Outcomes. (ree patients, all in Failed Group, experi-
enced relapse of AHRF during the first 48 hours from NIV
discontinuation (P< 0.01), and two of them died during the
hospitalization (both of them had received a DNR/DNI
order due to the severity of comorbidities) (Table 4). No
difference was observed between groups in regard to sec-
ondary outcomes.
4. Discussion
While other NIV weaning methods have been previously
described [3–6], our study is the first to describe a protocol
that implies the interruption of a ventilation session at the
time. None of the patients who completed weaning expe-
rienced AHRF relapse or died in the course of hospitali-
zation. A considerable proportion of patients, particularly
those younger, with a lower burden of comorbidities, but a
higher severity of COPD, was initiated on chronic domi-
ciliary NIV. Delirium should be taken into account among
the factors that can complicate the clinical course of ven-
tilated patients with AHRF due to AE-COPD even in the
weaning phase.
Despite the wide range of studies available on weaning
from invasive mechanical ventilation [19], few studies have
investigated the strategies to wean patients from NIV [3–6].
Similarly to Damas et al., who described a weaning protocol
that maintains the same number of sessions per day but
provides a progressive reduction of hours for each NIV
session, we did not observe recurrence of AHRF during
hospitalization after weaning [4]. Two recently published
RCTs by Sellares et al. and Lun et al. comparing immediate
vs. stepwise NIV withdrawal did not show any benefit from
the use of a weaning strategy in preventing relapse of AHRF
after NIV discontinuation, suggesting that NIV can be di-
rectly discontinued in COPD patients once the episode of
AHRF is solved [5, 6]. However, when looking at the
weaning phase itself, in our population, only one patient
failed the first weaning attempt because of worsening re-
spiratory failure. In the studies by Sellares et al. and Lun
et al., 19% and 44% of patients, respectively, in the direct
discontinuation groups failed the first withdrawal attempt
[5, 6]. (ese percentages were higher than in the stepwise
withdrawal (5% and 26%, respectively) [5, 6]. In spite of this
variable not being included among study outcomes, it is
important to consider that the application of a weaning
protocol may prevent respiratory function deterioration
even in the early stages of NIV interruption.
Furthermore, both the aforementioned studies recruited
only fully cooperative patients with a limited burden of
comorbidities. In a real-life setting, it is often necessary to
apply NIV to elderly patients with a high burden of
comorbidities (median Charlson comorbidity index in our
population ranged between 4 and 7), not fully cooperative
(as demonstrated by the prevalence of delirium in our co-
hort) and who received a DNR/DNI order (16% of cases in
our cohort). (ese frail patients often excluded from clinical
trials could be the ones most benefiting from weaning
protocols.
Only a minority of patients in our study completed the
weaning protocol, while a considerable proportion (39%)
was initiated on chronic domiciliary NIV. (ese patients
were younger, with a lower burden of comorbidities but a
higher severity of COPD compared to patients who com-
pleted weaning. (ese data suggest that patients who are
most likely to receive chronic domiciliary NIV are those with
a longer life expectancy and more severe COPD.
According to the CBM, 23% of patients in our cohort had
a diagnosis of delirium. A meta-analysis published in 2012
reported a prevalence of delirium of 37% in patients on NIV,
which was higher than the one generally presented in
hospitalized nonventilated patients (10–31%) [20]. Fur-
thermore, the risk of NIV failure in patients with delirium
was 2.12 times higher than in those without delirium. Our
study groups showed similar prevalence of delirium during
NIV, whereas, after NIV discontinuation, patients who
discontinued NIV ex abrupto showed a higher prevalence
compared to those who completed the weaning protocol.We
postulate that delirium, on a case-by-case basis, might be
both a cause and a consequence of NIV intolerance and






(N � 11) P value
Hospital length of stay and NIV duration,
median (IQR)
Hospital length of stay, days 10 (8–14) 11 (10–14) 11 (7–15) 0.76
NIV duration, days 4 (3–6) 11 (10–14) 2 (1–3) <0.01
Number of days with 3 NIV sessions 1 (1-2) 1 (0–3) 1 (0–3) 0.96
Number of days with 2 NIV sessions 1 (1-2) 2 (1–9) 0 (0-1) <0.01
Number of days with 1 NIV session 1 (1-2) 4 (0–5) 0 (0-1) < 0.01
NIV parameters, median (IQR)
Maximum IPAP (cm H2O) 16 (14–19) 21 (18–23) 17 (15–19) <0.01
Maximum EPAP (cm H2O) 6 (5–7) 8 (7-8) 6 (5–7) <0.01
IPAP (cm H2O) with domiciliary NIV — 19 (17–23) — —
EPAP (cm H2O) with domiciliary NIV — 8 (5–8) — —
EPAP, expiratory positive airway pressure; IQR, interquartile range 25th–75th percentile; IPAP, inspiratory positive airway pressure; NIV, noninvasive
ventilation.
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discontinuation. It is important to emphasize that patients
who had a sudden NIV interruption were also the oldest and
had the highest burden of comorbidities and the highest
percentage of DNR/DNI orders. All these factors, together
with the higher incidence of delirium after NIV discon-
tinuation, may have played a role in the worse clinical
outcomes (AHRF relapse after NIV discontinuation and in-
hospital mortality) observed in this group of patients.
However, as a potentially preventable and treatable condi-
tion, an early diagnosis is fundamental in frail patients, such
as those ventilated for AHRF, not only in the acute phase but
also in the weaning process.
Furthermore, although patients in the “Failed group”
interrupted NIV earlier compared to other groups, no
differences were observed in regard to the length of hospital
stay, once again indicating that these patients had a com-
plicated clinical condition that required a prolongation of
the hospitalization regardless of NIV use.
Limitations of the present study to be acknowledged
mainly address the small sample size and the monocentric
retrospective design, as well as the absence of a control group
to compare different weaning methods. Delirium was
assessed through a retrospective, although validated [18],
method that may have under- or overestimated the actual
incidence of this complication. Since our purpose was to
picture the use of a NIV weaning method in a real-life
scenario, we included in the study patients with AE-COPD
as primary diagnosis and secondary diagnosis of pneumonia
and congestive heart failure, as declared in Section 2.
However, the study population was too small to allow an-
alyses and speculations on the different application and
utility of a NIV weaning protocol according to the con-
comitant causes of AHRF.
Future studies should address the question of the utility
of NIV weaning and the best way to apply it. Assuming that
the paradigm “one size fits all” is incorrect, it would be of
paramount importance to determine which population
might benefit the most from the application of NIV weaning
protocols, including frail elderly patients.
5. Conclusions
In our cohort, the completion of a NIV weaning protocol
based upon the interruption of one of the three daily NIV
sessions at the time is associated with the absence of negative
outcomes, including AHRF relapse and in-hospital mortality.
Patients with AHRF should be carefully evaluated for pres-
ence of delirium both during and after NIV discontinuation.
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